Compare TAYD & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | CRBP |
|---|---|---|
| Founded | 1955 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.7M | 184.4M |
| IPO Year | 1995 | 2014 |
| Metric | TAYD | CRBP |
|---|---|---|
| Price | $57.03 | $9.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $70.00 | $45.50 |
| AVG Volume (30 Days) | 39.7K | ★ 464.9K |
| Earning Date | 03-31-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.24 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $46,292,725.00 | $4,822,272.00 |
| Revenue This Year | $0.25 | N/A |
| Revenue Next Year | $19.78 | $116.00 |
| P/E Ratio | $19.88 | ★ N/A |
| Revenue Growth | 3.84 | ★ 97.62 |
| 52 Week Low | $40.50 | $7.12 |
| 52 Week High | $90.37 | $20.56 |
| Indicator | TAYD | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 56.91 |
| Support Level | $56.80 | $7.42 |
| Resistance Level | $59.99 | $9.57 |
| Average True Range (ATR) | 2.74 | 0.50 |
| MACD | 0.16 | 0.21 |
| Stochastic Oscillator | 43.47 | 86.29 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.